Adial Pharma Stock Dips Amid FDA Meeting Rescheduling

Adial Pharmaceuticals shares are trading lower after the company announced the FDA meeting for their investigational drug AD04 has been rescheduled, delaying potential regulatory alignment and strategic partnerships.